Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) Revenue (2016 - 2026)

Agios Pharmaceuticals (AGIO) has disclosed Revenue for 14 consecutive years, with $20.7 million as the latest value for Q1 2026.

  • For Q1 2026, Revenue rose 137.75% year-over-year to $20.7 million; the TTM value through Mar 2026 reached $66.0 million, up 78.34%, while the annual FY2025 figure was $54.0 million, 48.03% up from the prior year.
  • Revenue hit $20.7 million in Q1 2026 for Agios Pharmaceuticals, up from $20.0 million in the prior quarter.
  • Across five years, Revenue topped out at $20.7 million in Q1 2026 and bottomed at $832000.0 in Q1 2022.
  • Average Revenue over 5 years is $9.0 million, with a median of $8.2 million recorded in 2024.
  • Year-over-year, Revenue surged 574.16% in 2023 and then rose 6.56% in 2025.
  • Agios Pharmaceuticals' Revenue stood at $4.3 million in 2022, then surged by 64.8% to $7.1 million in 2023, then skyrocketed by 51.06% to $10.7 million in 2024, then soared by 86.09% to $20.0 million in 2025, then grew by 3.9% to $20.7 million in 2026.
  • According to Business Quant data, Revenue over the past three periods came in at $20.7 million, $20.0 million, and $12.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.